Method for the treatment of central nervous system cancers and compositions related thereto
Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with, or in conjunction with other therapeutic agents.
1. A method for treating glioblastoma comprising administering a therapeutically-effective amount of progesterone, prodrug, or salt thereof to a subject in need thereof.
2. The method of claim 1 , wherein the subject is a human patient.
3. The method of claim 1 , wherein administration of progesterone, prodrug, or salt thereof can induce cell death in human glioblastoma cells, while having no detrimental effect on primary cortical neurons.
4. The method of claim 1 , wherein the subject is a human and is administered more than 50, 100, 200, 300 or 400 mg of progesterone, prodrug, or salt thereof daily.
5. The method of claim 1 , wherein the compound is administered in combination with a second chemotherapeutic agent.